Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Total Non-Current Liabilities (2021 - 2025)

Medicinova (MNOV) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities changed N/A to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $4.0 million for FY2025, N/A changed from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $4.0 million at Medicinova, up from $3.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $4.7 million in Q3 2022, with the low at $2.3 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $3.4 million, with a median of $3.1 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities tumbled 36.5% in 2023, then grew 26.46% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $3.0 million in 2021, then surged by 55.87% to $4.7 million in 2022, then decreased by 26.41% to $3.5 million in 2023, then decreased by 19.6% to $2.8 million in 2024, then surged by 42.9% to $4.0 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $4.0 million, $3.5 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.